Pharmaceutical News

RSS

Debiopharm granted license to develop and commercialise CDC25

Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

7 Sep 2009

Bacterium's S-layer secretes many therapeutic proteins

By adapting a single protein on the surface of the bacterium Caulobacter crescentus, researchers at the University of British Columbia have turned it into a protein production factory, making useful proteins that can act as vaccines and drugs. Dr. John Smit presented the findings at the Society for General Microbiology's meeting at Heriot-Watt University, Edinburgh, today (7 September).

7 Sep 2009

Cancer drug could restore memory deficits in Alzheimer's patients

A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of The Journal of Alzheimer's Disease: Volume 18:1.

7 Sep 2009

Opinion: Local drug production in developing countries; Obama's PEPFAR changes

The international community focuses on lowering drug prices as a means of improving access and "today its idea is local pharmaceutical production .

5 Sep 2009

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced the withdrawal of its European marketing authorization application (MAA) for lubiprostone, 24 mcg, for the indication of Chronic Idiopathic Constipation (CIC).

5 Sep 2009

Pharmavite LLC establishes direct-to-consumer sales company

Pharmavite LLC, the manufacturer and marketer of Nature Made® vitamins, minerals, herbs and other supplements and SOYJOY® snack bars, today announced the establishment of Pharmavite Direct LLC. Pharmavite Direct LLC is an internet-based, direct-to-consumer sales and marketing company.

5 Sep 2009

Sinovac to purchase H1N1 vaccine for the national stockpiling plan

Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Ministry of Industry and Information Technology of the People's Republic of China has issued the initial order to Sinovac to purchase H1N1 vaccine for the national stockpiling plan.

5 Sep 2009

Flu vaccinations now available at all 22 Target Clinic locations

Target(R) announces that flu vaccinations are now available at all 22 Target Clinic locations in Minnesota. The Centers for Disease Control and Prevention recommends nearly everyone protect themselves against this potentially serious illness.

5 Sep 2009

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

5 Sep 2009

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

5 Sep 2009

Discovery of two antibodies could move AIDS vaccine development forward

Scientists from Scripps Research Institute on Thursday announced they have discovered and isolated two antibodies "with the ability to neutralize [or block the action of] many strains of the AIDS virus, a discovery that might help create a long-sought vaccine against the deadly disease," Bloomberg reports.

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

Target Clinics in Maryland start selling seasonal flu vaccinations

Target(R) announces that flu vaccinations are now available at all six Target Clinic locations in Maryland. The Centers for Disease Control and Prevention recommends nearly everyone protect themselves against this potentially serious illness.

4 Sep 2009

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).

4 Sep 2009

Competition results in wide approval of Rev Vac safety syringe

Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies").

4 Sep 2009

Drive to collect unused prescription drugs starts on October 3

In an effort to keep unused prescription drugs out of the hands of pre-teens and teenagers, DDN executive Joe Otto enlisted the support of Menomonee Falls Police Chief Anna Ruzinski, Community Memorial Hospital, and his company. As a result, Community Memorial Hospital will serve as collection site when Waukesha County kicks off its first drug collection program on October 3.

4 Sep 2009

Filing and review of belatacept's license application accepted by the FDA

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the company’s submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation.

4 Sep 2009

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.

4 Sep 2009